Table 2 Characteristics of the patients enrolled in the CARRA Registry in the first 12 months of operation. All values are taken from the enrollment visit. Columns 3–5 are not mutually exclusive and patients may appear more than once
Frequency (%) or Median (25–75%) | ||||
|---|---|---|---|---|
Characteristic | All Participants (N = 1,192) | Recent Diagnosisa (N = 295) | New MTX Useb (N = 141) | New Biologic Useb (N = 147) |
Age at enrollment (years) | 12.4 (7.9–15.7) | 10.2 (4.8–14.1) | 11.5 (6.8–14.3) | 12.7 (7.2–16) |
Female | 887 (74%) | 201 (68%) | 109 (77%) | 105 (71%) |
Race/Ethnicity: | ||||
White | 962 (81%) | 240 (81%) | 112 (79%) | 115 (78%) |
Black/African-American | 58 (5%) | 15 (5%) | 5 (4%) | 8 (5%) |
Asian | 48 (4%) | 15 (5%) | 8 (6%) | 4 (3%) |
Hispanic/Latino | 135 (11%) | 30 (10%) | 14 (10%) | 20 (14%) |
Middle Eastern/North African | 5 (0.4%) | 3 (1%) | 1 (0.7%) | 1 (0.7%) |
Native American, American Indian, Alaskan Native | 15 (1%) | 2 (0.7%) | 1 (0.7%) | 2 (1%) |
Native Hawaiian or Other Pacific Islander | 12 (1%) | 4 (1%) | 2 (1%) | 1 (0.7%) |
Private health insurance | 890 (75%) | 217 (74%) | 101 (72%) | 112 (76%) |
Disease duration (years) | 2.6 (0.5–6.2) | 0.1 (0–0.3) | 1.1 (0–4) | 2.2 (0.5–6.1) |
ILAR category: | ||||
Oligoarthritis, persistent | 152 (13%) | 90 (31%) | 28 (20%) | 16 (11%) |
Oligoarthritis, extended | 102 (9%) | 6 (2%) | 5 (4%) | 11 (7%) |
Polyarthritis, RF- | 510 (43%) | 88 (30%) | 66 (47%) | 62 (42%) |
Polyarthritis, RF+ | 101 (8%) | 18 (6%) | 14 (10%) | 14 (10%) |
Psoriatic arthritis | 57 (5%) | 20 (7%) | 9 (6%) | 9 (6%) |
Enthesitis related arthritis | 104 (9%) | 44 (15%) | 11 (8%) | 20 (14%) |
Systemic arthritis | 154 (13%) | 26 (9%) | 6 (4%) | 13 (9%) |
Undifferentiated arthritis | 12 (1%) | 3 (1%) | 2 (1%) | 2 (1%) |
ANA+ | 457/1041 (38%) | 107/255 (36%) | 64/128 (45%) | 64/134 (44%) |
RF+ | 111/907 (9%) | 24/213 (8%) | 17/107 (12%) | 15/118 (10%) |
Anti-CCP+ | 91/585 (8%) | 20/129 (7%) | 17/74 (12%) | 14/73 (10%) |
HLA-B27+ | 98/608 (8%) | 32/179 (11%) | 15/75 (11%) | 16/83 (11%) |
Polyarthritis course | 895 (75%) | 151 (51%) | 100 (71%) | 107 (73%) |
Uveitis, ever | 94 (8%) | 3 (1%) | 8 (6%) | 19 (13%) |
Number of active joints | 1 (0–3) | 2 (1–6) | 3 (1–6) | 3 (1–5.75) |
Physician global assessment | 1.5 (0–3.0) | 3 (1.5–5) | 3 (1.75–4.25) | 3 (2–5) |
CHAQ score | 0.125 (0–0.625) | 0.375 (0–0.875) | 0.25 (0–1) | 0.5 (0–1) |
ESR | 8 (5–17) | 9 (5–28) | 9 (6–23) | 9 (5–27) |
CRP | 0.6 (0.2–1.7) | 0.8 (0.3–1.7) | 1.0 (0.5–3.0) | 0.8 (0.5–2.6) |